First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts

Nuclear Medicine and Biology

Volumn 40, Issue 5, 2013, Pages 618-624

  Persson, Morten ^a,b,c,d   Liu, Hongguang ^d   Madsen, Jacob ^b   Cheng, Zhen ^d   Kjaer, Andreas ^a,b,c  

^a The Danish Chinese Center for Proteases and Cancer   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

PET 18F; Prostate cancer; UPAR

Indexed keywords

AE 105; AE 152; AIF NOTA AE 105 F 18; NOTA AE 105; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HUMANS; ISOTOPE LABELING; LIGANDS; MALE; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOCHEMISTRY; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84878206122     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.03.001     Document Type: Article

References (29)

1. Rasch M.G., Lund I.K., Almasi C.E., Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008, 13:6752-6762.
2. Miyake H., Hara I., Yamanaka K., Gohji K., Arakawa S., Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate May 1999, 39(2):123-129.
3. Miyake H., Hara I., Yamanaka K., Arakawa S., Kamidono S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol Mar. 1999, 14(3):535-541.
4. Piironen T., Haese A., Huland H., Steuber T., Christensen I.J., Brunner N., et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem May 2006, 52(5):838-844.
5. Steuber T., Vickers A., Haese A., Kattan M.W., Eastham J.A., Scardino P.T., et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer Apr. 2007, 120(7):1499-1504.
6. Gupta A., Lotan Y., Ashfaq R., Roehrborn C.G., Raj G.V., Aragaki C.C., et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol May 2009, 55(5):1124-1133.
7. Nogueira L., Corradi R., Eastham J.A. Other biomarkers for detecting prostate cancer. BJU Int Jan. 2010, 105(2):166-169.
8. Shariat S.F., Semjonow A., Lilja H., Savage C., Vickers A.J., Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol Jun. 2011, 50:61-75.
9. Shariat S.F., Roehrborn C.G., McConnell J.D., Park S., Alam N., Wheeler T.M., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol Feb. 2007, 25(4):349-355.
10. Rabbani S.A., Ateeq B., Arakelian A., Valentino M.L., Shaw D.E., Dauffenbach L.M., et al. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia Oct. 2010, 12(10):778-788.
11. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem Oct. 2005, 280(43):36529-36540.
12. Kriegbaum M.C., Persson M., Haldager L., Alpízar-Alpízar W., Jacobsen B., Gårdsvoll H., et al. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets Nov. 2011, 12(12):1711-1728.
13. Persson M., Madsen J., Ostergaard S., Jensen M.M., Jorgensen J.T., Juhl K., et al. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med Jan. 2012, 53(1):138-145.
14. Persson M., Madsen J., Ostergaard S., Ploug M., Kjær A. (68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol May 2012, 39(4):560-569.
15. McBride W.J., Sharkey R.M., Karacay H., D'Souza C.A., Rossi E.A., Laverman P., et al. A novel method of 18F radiolabeling for PET. J Nucl Med Jun. 2009, 50(6):991-998.
16. Laverman P., McBride W.J., Sharkey R.M., Eek A., Joosten L., Oyen W.J., et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med Mar. 2010, 51(3):454-461.
17. McBride W.J., D'Souza C.A., Sharkey R.M., Karacay H., Rossi E.A., Chang C.H., et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem Jul. 2010, 21(7):1331-1340.
18. D'Souza C.A., McBride W.J., Sharkey R.M., Todaro L.J., Goldenberg D.M. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem Sep. 2011, 22(9):1793-1803.
19. Liu S., Liu H., Jiang H., Xu Y., Zhang H., Cheng Z. One-step radiosynthesis of (1)(8)F-AlF-NOTA-RGD(2) for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging Sep. 2011, 38(9):1732-1741.
20. Gao H., Lang L., Guo N., Cao F., Quan Q., Hu S., et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging Apr. 2012, 39(4):683-692.
21. Dijkgraaf I., Franssen G.M., McBride W.J., D'Souza C.A., Laverman P., Smith C.J., et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med Jun. 2012, 53(6):947-952.
22. Heskamp S., Laverman P., Rosik D., Boschetti F., van der Graaf W.T., Oyen W.J., et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med Jan. 2012, 53(1):146-153.
23. Hoigebazar L., Jeong J.M., Lee J.Y., Shetty D., Yang B.Y., Lee Y.S., et al. Syntheses of 2-nitroimidazole derivatives conjugated with 1,4,7-triazacyclononane-N, N'-diacetic acid labeled with F-18 using an aluminum complex method for hypoxia imaging. J Med Chem Apr. 2012, 55(7):3155-3162.
24. Laverman P., D'Souza C.A., Eek A., McBride W.J., Sharkey R.M., Oyen W.J., et al. Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol Apr. 2012, 33(2):427-434.
25. Ploug M., Ostergaard S., Gårdsvoll H., Kovalski K., Holst-Hansen C., Holm A., et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry Oct. 2001, 40(40):12157-12168.
26. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003, 9(19):1499-1528.
27. McBride W.J., D'Souza C.A., Sharkey R.M., Goldenberg D.M. The radiolabeling of proteins by the [18F]AlF method. Appl Radiat Isot Jan. 2012, 70(1):200-204.
28. Persson M., Rasmussen P., Madsen J., Ploug M., Kjaer A. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using (177)Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol Oct. 2012, 39(7):962-969.
29. Kurdziel K.A., Shih J.H., Apolo A.B., Lindenberg L., Mena E., McKinney Y.Y., et al. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med Aug. 2012, 53(8):1175-1184.